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ABSTRACT
Part 1:
Peptoids are isomers of peptides where the side chains are on the nitrogens
instead of the carbons, which have been developed for a variety of biomedical, nano, and
materials applications. Conventional peptoid synthesis uses molar concentrations of
reagents and hours of reaction time per residue, thus practically limiting the lengths
of peptoids. Recently, we have managed to improve yields and make peptoids of
unprecedented lengths while reducing the reaction times and concentrations of reagents.
Indeed, we have demonstrated that the conventional longer reaction times degrade
the peptoids and lead to lower purities. In addition, by using microwave conditions, we
successfully incorporate sterically bulky, chiral side chains into peptoids at
concentrations lower than have ever been reported. We hereby report the
longest peptoid ever synthesized, a 120-mer decablock copolymer that is nearly perfectly
monodisperse without any purification.

Part 2:
Creatine is a nitrogen-containing compound that helps supply energy to the cells
in the body. This is done by accepting a phosphate from excess ATP to form
phosphocreatine which is used to replenish ATP when needed. Half of the creatine in
adults is obtained through their diet while the other half is synthesized by the body.
However, creatine requires a transporter to cross the blood brain barrier (BBB) and
mutation in the gene encoding for the creatine transporter, slc6a8 (creatine transporter
deficiency, CTD) causes severe X-linked intellectual disability which accounts for
approximately 2% of all X-Linked Intellectual Deficiency patients. CTD causes
ii

developmental delays, seizures, autistic features, speech impairment, brain atrophy and
intellectual disabilities. Without a working creatine transporter, creatine cannot pass
through BBB, therefore, analogs of creatine derivatives that could more readily diffuse
through the BBB could potentially be used to treat CTD. Hence, the focus for this project
was to synthesize creatine derivatives that could potentially cross the BBB without the
need of a creatine transporter. This was done by modifying the creatine with substituents
that are hydrophobic so that the derivative becomes lipophilic enough to cross the BBB.
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CHAPTER ONE
SOLID PHASE PEPTOID SYNTHESIS (SPPS)
Introduction
Peptoids (poly-N-substituted glycines) are similar in structure to peptides with the
only difference being the position of the side chain. In peptides the side chain is located
on the α-carbon while in peptoids the side chain is positioned at the nitrogen of the
backbone instead of the α-carbon.1, 2 (Figure 1.1). This minor change in structure has
tremendous effects for peptoid oligomers. While peptides are prone to protease
degradation, peptoids are not.3. Changing the side chain connectivity eliminates the
hydrogen bond donor (NH group) in peptoids, thus eliminating the ability for regular
hydrogen bonding in peptoids, making peptoids resistant to proteolysis.3

Figure1.1. The difference in the structures of peptides (top) and peptoids (bottom).
Peptides usually have short half-lives and are degraded very quickly by proteases
in vivo making them inefficient as drugs.4. Therefore, peptoids are important because
they may eventually replace peptide drugs due to their proteolytic stability.5. Since
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peptoids are so similar in structure to peptides many groups have studied peptoid analogs
of peptide therapeutics for a variety of applications.6
To truly mimic peptides, peptoids must have the ability to form structures.
Changing the position of the side chain not only eliminates the ability for H-bonding, but
also eliminates the chirality of the polymer.1. Without the backbone chirality, peptoids
are unable to form stable secondary and tertiary structures. However, this can be easily
solved by incorporating chiral amines into the peptoid chains.3, 7, 8. Chiral amine
incorporation will allow the peptoid to form secondary structures which is stabilized by
steric interaction, rather than hydrogen bonding. However, incorporating chiral amines
reduces the purity and yield of peptoid synthesis. Therefore one of the aims of my
research is to be able to synthesize peptoids incorporating chiral amine residues with
higher purity and yield of the peptoid oligomer.
Methods for Peptoid Synthesis
There are multiple methods to synthesizing peptoids. The original method for the
synthesis of peptoids is similar to solid phase peptide synthesis (SPPS) 9 (Scheme 1.1).
In this method, the N-Fmoc protected amino acid is activated and reacted with an amine
on the resin. Removing the Fmoc group regenerates a reactive amine which can react
with another Fmoc protected amino acid. This process is repeated until the desired length
is reached and the final peptoid is cleaved from the resin using standard methods.
Scheme 1.1. Solid Phase Peptoid Synthesis incorporating pre-synthesized, Fmocprotected N-substituted glycine monomers.
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However, the Fmoc-protected N-substituted glycines are not commercially
available and need to be synthesized beforehand. Furthermore, removal of the Fmoc
group after each coupling requires time and reagents. Due to these disadvantages, a new
method was developed.1
In 1992 Ron Zuckermann developed the submonomer method for the synthesis of
peptoid oligomers1 which is the predominant method used today (Scheme 1.2). The
submonomer approach refers to the fact that the carboxylic acid and amine portions of the
amino acid are installed in separate steps. In this method peptoids are synthesized from
two readily available submonomers: a haloacetic acid (usually bromoacetic acid) and a
primary amine. In the acylation step the haloacetic acid is activated (usually by
diisopropylcarbodiimide, DIC) and reacts with the amine on the resin to generate a
monohaloacetamide. In the amination step, the halide is displaced by the primary amine
to generate the peptoid monomer. The site-separation inherent in solid phase synthesis
avoids the common dialkylation side reaction that would occur if this chemistry were
performed in solution. The two step cycle is repeated until the desired length is reach.
Advantages of the submonomer method is the abundant selection of primary amines that
are commercially available and relatively inexpensive, therefore diverse side chains can
be readily incorporated.2,9

3

Scheme 1.2. Solid Phase Submonomer Peptoid Synthesis Method.

For the submonomer method, reaction times of 1.5-3 hours per residue are
standard.2,9 Therefore, synthesizing a short oligomer, such as a pentamer, would take up
to 12.5 hours, making this method not ideal for synthesizing long peptoid polymer such
as 50mers to 100mers. Attempts to use microwave irradiation to accelerate the synthesis
were not transformative and have not been widely adopted10.
Conclusion
The problem we want to address is, how can we synthesis longer peptoid
polymers, (50mer or larger) without sacrificing time and purity? As mentioned earlier
due to the loss in ability to hydrogen bond, chiral amines are regularly incorporated to
form secondary and tertiary structures. However, the α-branching makes both steps in
the submonomer synthesis more difficult. Can we improve the yields, purity, and
reaction times for these amines as well? Therefore, our aim was to identify novel
condition for the synthesis of peptoid oligomers and polymers using chiral and achiral
amines while improving the yields, purity and reducing the reaction time. The yields and

4

purity of peptoid oligomers and polymers synthesized were determined by MALDI-MS
and HPLC.
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CHAPTER TWO
FASTER AND GREENER: ONE MINUTE REACTIONS FOR SYNTHESIS OF
PEPTOID OLIGOMERS AND POLYMERS
Introduction
Because of their sequence specificity and chemical diversity, peptoids (poly-Nsubstituted glycines) were proposed in the 1990s1 as a bridge between the sequence
control of biological polymers and the chemical diversity of commodity polymers.
Recent work by the Segalman and Zuckermann groups on the material properties of
sequence-specific peptoid oligomers has almost exclusively focused on peptoids
oligomers 18-36mer in lengths (3-6 kDa), likely far below the critical entanglement
(restriction of polymer chain movement due to being entangle with other chains) length
of peptoids (which has never been measured).2 Although peptoid polymers have been
elegantly synthesized using solution polymerization conditions by Zhang, Luxenhofer
and others, 2 such polymers lack the precise sequence control that underlay the original
promise of bridging biological and commodity polymers
Historically, investigations into peptoid synthesis conditions often seek universal
conditions that cover a wide variety of potential side-chain chemistry and therefore lead
to long reaction times and high concentrations.3-5 In contrast, we are motivated to seek
shorter reaction times and lower reagent concentrations for some of the most commonly
used peptoid side chains.6
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Figure 1. (A) Submonomer synthesis scheme. (B) Side chains used in this study and the
residue code. Side chains were derived from commercial amines (Nbu: butylamine;
Nme: methoxyethylamine; Npp: phenylpropylamine Npe: phenylethylamine; Ntf: (2tetrahydrofuryl) methylamine; Nspe: (S)-1-phenylethylamine)
Results and Discussion
The original submonomer synthesis (Figure 1A) 3 utilized 3 hours of reaction
time per residue to ensure high coupling efficiency for a diverse range of amines,3 and
such conditions are representative of the field in general.6 Given those long reaction
times, multiple groups have investigated accelerating peptoid synthesis using microwave
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irradiation, resulting in reaction times between 30 s to 5 m per step, with moderately
improved yields.3,4,7 The limitation of these attempts was the poor choice of control
experiments. It is difficult to compare results when the microwave irradiation times were
completely different from the unheated reaction times. Reaction times of 90 seconds
under microwave irradiation were compared to unheated reaction times of 1 hour instead
of 90 seconds. As discussed below, long reaction times are deleterious to the peptoid
synthesis. Although these methods have not been broadly adopted, they are congruent
with work in peptide synthesis to reduce reaction times with alternative activation
reagents7 and microwave heating.9
We now report that peptoid synthesis of long oligomers and even polymers with
reaction times of one minute with no heating is not only feasible but results in higher
yields than previously reported peptoid synthesis conditions, even in the case of the
sterically-challenging α-branched chiral amines. We also systematically sought the
lowest possible reagent concentrations for peptoid synthesis, and demonstrate that
reaction concentrations as low as 0.25M yield very pure peptoids. Notably, validation of
synthetic methodology in the peptoid field is usually reported using trimers and
pentamers,3,5,10-12 but the vast majority of peptoid applications utilize longer oligomers,6
thus requiring end users to continually validate and modify any reported synthetic
conditions. To avoid this common pitfall, peptoid decamers and eicosamers (20mers) are
uniformly used within to validate reaction conditions.
Initially, we tested the viability of one minute reaction times with four sterically
unhindered α,α-unbranched amines to synthesize peptoid eicosamers 1-4 (Table 1).
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Bromoacetic acid and DIC (BrAA/DIC) concentrations of 0.4M were used for the
acylation, consistent with the generally overlooked decade-old report that 0.4M
BrAA/DIC for 5 minutes are more effective conditions than the commonly employed
1.2M for 20-60 minutes.10 Amine concentrations of 0.5M were used, and both acylation
and alkylation conditions use the lowest of reported concentrations.6 Two peptoid
20mers were also synthesized at 1 mmol scales and cleaved to quantify yields; both
peptoids had yields of ~70% (Supporting Information).
Table 1. Peptoids and crude purities in this study
Compound Compounda
[Reagent]c Reaction timed

HPLC
Purityf
(Nbu)20
0.4/0.5
1
78
1
(Nme)20
0.4/0.5
1
91
2
(Npe)20
0.4/0.5
1
69
3
(Ntf)20
0.4/0.5
1
79
4
(Nspe)10
1.2/4.5
1
87
5
(Nbu)
0.2/0.15
5
84
6
10
(Nme)20
0.2/0.15
5
79
7
e
(Nspe)10
0.4/0.25
5
80
8
(Nme)15(Npe)15 0.4/0.5
1
82
9
(Nbu)25(Nme)25 0.4/0.5
1
70
10
(Nme)50
0.4/0.5
1
82
11
b
120mer
0.4/0.5
1
74
12
a
b
Side chain residue codes and structures are shown in Figure 1B. 120mer sequence:
Ndop12Nbu12Nme12Npe12Nme12Npe12Nbu12Nme12Npp12Nme12 cReagent concentrations are
reported in molarity. dEach reaction was done twice to ensure proper mixing. eMicrowave
heating was utilized. fHPLC chromatograms are shown in Supplementary Information.
Crude purities for the eicosamers ranged from 69-91% (Table 1, Figure 2),
demonstrating the utility of one minute room temperature reactions for synthesis of
peptoid oligomers. Somewhat similar reaction times have previously been reported as
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successful at synthesizing notably shorter nonamers of α,α-unbranched amines without
microwave irradiation although at substantially higher reagent concentrations (2M
BrAA/DIC & 1M amine, vs. 0.4M BrAA/DIC & 0.5M amine here), but no data or
purities were reported.5
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Figure 2. HPLC chromatograms and MALDI-TOF mass spectra for unpurified peptoids
(1-4). Due to diketopiperazine elimination occurring in rink amide resin, MALDI-TOF
mass spectra for Npe20 was run using chlorotrityl chloride resin.
To evaluate whether these faster reaction times are also possible for chiral, αbranched amines, we used the prototypical Nspe (Figure 1B). Four synthetic conditions
were investigated: (a) one minute acylations with 0.4M reagents, one minute alkylations
with 0.5M amine; (b) one minute acylations with 0.4M reagents, five minute alkylations
with 1.5M amine; (c) five minute acylations with 1.2M reagents, one minute alkylations
with 0.5M reagents; and (d) five minute acylations with 1.2M reagents, five minute
alkylations with 1.5M amine (Supporting Information). Our results revealed that 1.2M
BrAA/DIC and 4.5M amine were sufficient to synthesize compound 5 at room
temperature with reaction times of one minute. While the 4.5M amine concentration
would produce unacceptable levels of waste if the solution was discarded after each use,
we also tested 7M Nspe amine concentrations, which performed similarly to the 4.5M
concentrations. Thus, reusing a 7M Nspe solution between couplings, even accounting
for a drop in concentration between successive cycles would yield low levels of waste
with one minute long syntheses. Clearly, microwave heating is not required to synthesize
peptoids of high yield.
We then sought to identify the lowest possible concentrations that would yield
pure peptoid decamers. Room temperature conditions were tested for α,α-unsubstituted
side chains, leading to concentrations as low as 0.2M BrAA/DIC and 0.15M amine to
synthesizer decameric peptoids 6 and 7 in high yield. These concentrations are lower
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than concentrations that were previously reported as the bare minimum required for
successful peptoid synthesis.6 Inspired by this result, we sought to identify the lowest
possible concentrations for α-branch chiral side chains. Since these side chains are
derived from chiral amines they are usually far more expensive, thus leading to a greater
incentive to use lower concentrations. For peptoid 8 (same as peptoid 5 but synthesized
using microwave conditions), was synthesized with 0.4M BrAA/DIC and 0.25M amine
(Figure 3). All of these combinations are the lowest concentrations for peptoid synthesis
ever reported, and notably represent a much better use for microwave irradiation in
reducing the concentration of expensive chiral amines and their consequent waste.

14

Figure 3. HPLC chromatograms and MALDI-TOF mass spectra for unpurified peptoids
(5-8).
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Figure 4. HPLC chromatograms and MALDI-TOF mass spectra for unpurified peptoid
polymers (9-12).
Since the yields for our peptoids are equal to or higher than previous reports at
higher concentrations and reagent times, we investigated two possible mechanisms to
account for these surprisingly high yields. First, most robotic synthesizers add BrAA
solutions to the resin followed by DIC with delays of many seconds or as long as several
minutes between the addition of the two reagents. This delay could potentially enable the
secondary amine on the resin to be alkylated by the bromoacetic acid before the addition
of the DIC enables the acylation to proceed. To test this possibility, we synthesized
Nme10 four times, using delay times between addition of the BrAA and DIC of 1 second,
30 seconds, 1 minute, and 5 minutes. This delay did not impact the yields (data not
shown), possibly due to transient protonation of the amine by the carboxylic acid that is
reversed upon addition of the mildly basic DIC.
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Second, it is possible that unnecessarily long reaction times degrade the peptoid
chain on the resin. Therefore, we synthesized Nme20, then separately stirred the peptoid
while still on resin in the presence of 1.2M BrAA, 1.2M DIC, 1.2M BrAA/DIC, or 1M
methoxyethylamine for 24 hours. Notable decomposition occurred in the presence of
1.2M BrAA/DIC, but not in the presence of any of the three individual reagents (data not
shown). These results are consistent with the previous report that lower BrAA/DIC
concentrations are advantageous.10

Figure 5. HPLC chromatograms and MALDI-TOF mass spectra for unpurified Nme20
in 1.2M BrAA/DIC for 24 hours.
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While peptoid polymers and block copolymers have been synthesized using
polymer synthesis techniques,2 those syntheses do not enable perfect control of the
primary sequence of the resulting polymer. Therefore, we synthesized the 30mers
peptoid 9, two 50mers (peptoid 10 and 11), and a 120mer decablock peptoid polymer 12
(Figure 4). Peptoid 12 has a molecular weight of nearly 17 kDa, thus putting it at similar
molecular weights to peptoid polymers synthesized using solution N-carboxyanhydride
chemistry.13 This peptoid polymer finally bridges the chemical diversity of commodity
polymers with the sequence specificity of biological polymers and fulfills the two-decade
old promise of peptoids.1,14 Since, unlike other polyamide polymers, peptoid polymers
are melt-processable,14 the synthesis of peptoid polymers with perfect sequence control
also enables important new studies in polymer chemistry and physics that could not have
been tackled previously.
Conclusion
We have hereby demonstrated one minute reaction times and the lowest reagent
concentrations ever reported for peptoid synthesis using some of the most common side
chains used in peptoids. We have also demonstrated that the longer reaction times and
higher concentrations used during acetylation are directly responsible for the lower yields
regularly observed in the literature. These faster and greener conditions for peptoid
synthesis now enable regular and straightforward synthesis of peptoid polymers that will
be useful in the creation of peptoid proteins for biophysical studies and therapeutic
applications, as well as in the study of polymer behavior.15-18
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Supplementary information
Material: Bromoacetic acid, DMF and all amines were purchased from Alfa Aesar.
Rink Amide resin was purchased from Apptec. Diisocarbodiimide (DIC) was purchased
from Oakwood Chemicals. All chemicals were used in reaction without further
purification.
General. Reverse-Phase HPLC was performed using a Shimazu-LC Solution with DGU20A3 degasser, LC-20AD Liquid Chromatograph, CBM-20AD Communicate Bus
Module, SPD-20A UV-Vis detector, and CTO-20AC Column Oven. Mobile Phase A =
0.1% TFA in water; Mobile Phase B = 0.1% TFA in HPLC grade acetonitrile. Purities
were determined by integration at 220nm. A blank was run after each sample injection
and each blank was subtracted from the sample to obtain the purity of the sample. A C4
Column (Higgins Analytical, Inc, PROTO 200 C4 5μm 250 x 2.1mm) was used for the
analysis of all peptoid polymers. MALDI-MS was obtain using Bruker model Compass
Flex Series 1.4 (part number 269833), FlexControl 3.4.78.0 and FlexAnalysis 3.4.50.0.
Microwave Instrumentation. All microwave reactions were carried out in a Multiwave
Pro with Instrument Software Version 2.40 from Anton Paar.
Microwave Synthesis Protocol:
1 minute Microwave synthesis for 0.4 M BrAA and DIC, 0.5 M Nspe 10mer. 600 mg
Fmoc-protected Rink amide resin (100-200mesh, 0.49 mmol/g) were weighed in a 10 mL
fritted syringe with a stopcock to prevent leaks. Rink amide resin was swelled in DMF (6
mL X 3). The Fmoc group was deprotected with 20% 4-methylpiperidine in DMF (6 mL
x2) and allowed to stir for 2 minutes each time. Once deprotected, the resin was washed
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with DMF (6 mL x 3). Since resin will have to be transferred from syringe to microwave
tubes, stock solutions were made at twice the concentration of the standard solution (0.8
M BrAA and 1.0 M Nspe). This stock solution will be used in the microwave reaction
and diluted to the correct concentration (0.4 M BrAA. 0.5 M Nspe). For the acylation
step, BrAA in DMF solution (0.8 M, 2.616 mL) and DIC (0.8 M, 0.872 mL) was added to
the deprotected rink amide resin. This solution was then transferred to the microwave
tube. During the transfer, not all the solution and the resin will transfer over, therefore 1
mL of DMF is added to the syringe to rinse out what still remain and transfer back to the
microwave tube. This was done three times (total of 3 mL) to lower the stock solution
concentration back to the standard solution concentration of 0.4 M BrAA and DIC. The
acylation step is then performed using the microwave for 1 min at 50°C. The sample was
transferred back to the fritted syringe and washed with DMF (6mL x 3). After the wash
step, 1.0 M Nspe (3 mL) stock solution in DMF was added to the resin. This solution
was then transferred to the microwave tube. As mentioned earlier, during the transfer
step, not all the resin will transfer over and DMF is added 1 mL at a time (total of 3 mL)
to the syringe to rinse out what still remains and is added to the microwave tube. This
will lower the amine stock solution concentration (1.0 M) back to the standard
concentration of (0.5M) Nspe. Once the solution was transferred, the amination step was
performed using the microwave reactor for 1min at 95°C. Once the amination step
finished, the solution was then transferred back in to the fritted syringe. The sample was
washed with DMF (6 mL X 3). The acylation and amination steps were repeated until
the desired length was reached.

23

1 minute Microwave synthesis for 0.4 M BrAA and DIC, 0.25 M Nspe 10mer.
Reaction conditions were the same as mentioned above. The stock solution was changed
to 0.5 M for the Nspe.
1 minute Microwave synthesis for 0.25 M BrAA and DIC, 0.5 M Nspe 10mer.
Reaction conditions were the same as mentioned above. The stock solution was changed
to 0.5 M for the BrAA.
1 minute Microwave synthesis for 0.25 M BrAA and DIC, 0.2 5 M Nspe 10mer.
Reaction conditions were the same as mentioned above. The stock solution was changed
to 0.5 M for both the BrAA and the Nspe. During the acylation step, the amount of
BrAA and DIC was change to 2.76 mL of BrAA and 0.920 mL of DIC.
10 minute Microwave synthesis for 0.4 M BrAA and DIC, 0.25 M Nspe (for both
10mer and 20mer). The procedure is the same as mentioned above for the 1 minute
reaction. The reaction conditions were changed to 5 min acylation at 45°C and 10 min
amination at 95°C.
NOTE: Each time the solution is transferred from the syringe to the microwave tube for
the microwave synthesis, the syringe was rinsed three times with 1 mL DMF to remove
all residues and to dilute stock solution concentration to standard concentration.
Each time the solution was transferred from the microwave tube back to the
syringe, the microwave tube was rinse with DMF three times to make remove all residue
and to clean the microwave tube.
Standard Synthesis Protocol. General procedure: Approximately 100mg of Fmocproctected Rink amide resin (100-200 mesh, 0.49 mmol/g) was weighed into a fritted
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syringe with a stopcock to prevent leaks and swelled in DMF (1 mL x 2) for 1 minute.
The resin was deprotected with 20% 4-methylpiperidine in DMF (1 mL x 2) for 1 minute
and washed with DMF. (1 mL, 15 seconds X 3). 0.4 M bromoacetic acid (BrAA) in
DMF (1 mL) and 0.4 M DIC (64 μL) was added. The syringe was placed in a beaker and
the solution was stirred on a stir plate for 1 minute at room temperature (1 mL x 2 at 1
minute each time). The reaction mixture was filtered and washed with DMF (1 mL, 15
seconds X 3). After the wash step, 0.5 M amine in DMF (1 mL) was added and stirred at
room temperature for 1 min (1 mL x 2 at 1 minute each time), follow by another DMF
was step (15 seconds X 3). This two-step process was repeated until the desired length
was obtained. Once the desired length was obtained, the resin was washed with DMF (15
seconds x 3) and dichloromethane (DCM) (30 seconds x 2). The stopcock was left open
and the sample was allow to air dry.
Small scale Peptoid Cleavage Protocol. A small amount of resin (enough to coat the
bottom of a 200 μL pipette tip) were placed in an Eppendorf tube. The resin was cleaved
with 95% Trifluoroacetic acid in 5% H2O (100 μL) for 10 minutes. The resin was dried
under a stream of nitrogen. Once dried, the sample was resuspended in a 50:50 mixture
of acetonitrile and water (200 μL). The sample was filtered into another eppendorf tube
to remove the resin. This small scale cleavage were used for MALDI identification and
HPLC analysis before large scale full scale cleavage were performed.
Cleavage of Chiral Nspe Peptoids:
Cleavage of the samples was performed on a small scale using a 95%: 5% (TFA: H2O)
mixture for 2 minutes. After 2 minutes the solution was dried with N2 gas. Once dry, the
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sample was resuspended in a 50:50 ACN: H2O solution. The solution was then filtered to
remove the resin.
HPLC Method. The peptoids were analyzed by HPLC using 220nm wavelength. A C4
column was used for all peptoid analyses. The gradient elution was 25-95% mobile
phase B (MPB) for 16mins, hold at 95% MPB for 5 mins and back to 95-25% MPB for 2
mins and held at 25% MPB for 6 mins for a total of 30 min run time.
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CHAPTER THREE
CREATINE OVERVIEW
Introduction
Creatine (Fig 1) is an amino acid analog that helps to maintain energy pools in
cells.1-2 This is done by accepting phosphates from excess ATP (the main source of
energy in the cell) during resting states to form creatine phosphate, and using the creatine
phosphate to rapidly replenish ATP levels when needed.1,3 (Fig 2). This process is
catalyzed by the enzyme creatine kinase (CK) which is ubiquitous in every cell in our
body.1-2

Half of the creatine in adults comes from their diet, usually from meat and dairy
products,1-2,4 while the remainder is synthesized within the body in a two-step process1,5
as shown in Fig 3. Creatine is synthesized from two amino acids, arginine and glycine,
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with the help of two enzymes; an amidinotransferase (AGAT) and a methyltransferase
(GAMT).2 AGAT catalyzes the transfer of an amidine from arginine to glycine, yielding
ornithine and guanidinoacetate.2 Gaunidinoacetate is then methylated by the enzyme
GAMT through the transfer of a methyl group from S-adenosyl-L-methionine to give
creatine.2 Most of the creatine synthesis and usage occurs in muscle tissue, but it can be
transported in and out of cells by the Creatine Transporter (CrT, encoded by the gene
slc6a8) and utilized by other tissues.1-2
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Mutations in the AGAT, GAMT and CrT can cause creatine deficiency
syndromes.1-2,6-7 This affect is most notable in the central nervous system (CNS), with
almost no creatine found in the CNS as measured by 31P magnetic resonance imaging.8
Creatine deficiency syndromes lead to a wide variety of complex pathologies, but the two
syndromes resulting from mutations in the biosynthetic pathway (AGAT and GAMT) can
be treated with dietary creatine. However, mutations in the gene encoding for the
creatine transporter, slc6a8 (creatine transporter deficiency, CTD), have no current
treatment (symptoms are treated with medication to little avail).1 Creatine transporter
deficiency manifests as a severe X-linked intellectual disability and is the second most
common cause of XLID after fragile X-syndrome.7 Specific symptoms include
developmental delays, seizures, autistic features, speech impairments, brain atrophy and
intellectual disabilities.1, 2, 7-9 Creatine transporter deficiency is projected to affect
approximately one million males world-wide with milder disabilities in carrier women.9
Without a working creatine transporter, creatine cannot pass through the Blood
Brain Barrier (BBB).10. Therefore, analogs of creatine derivatives that could more readily
diffuse through the BBB could potentially be used to treat CTD.3,11-12
The crystal structure of human brain type creatine kinase with creatine, ADP, and
the catalytic Mg2+ bound,13 reveals that when creatine binds to the binding site, the
methyl group protrudes out of the binding site (Fig 4) while the rest of the molecule is
tightly bound. We therefore propose that modifying creatine with larger substituents on
the nitrogen replacing the methyl group would be the most likely to still function with
creatine kinase. This hypothesis is indeed consistent with the substitution of an ethylene
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bridge to the guanidine and an ethyl substituent on the nitrogen that were observed as the
most efficacious in a 44 year-old-study.11 The same study also observed significant loss
of activity with creatine kinase if large substitutions were made on the α-carbon or the
carboxylic acid end.11 Additionally, a more recent study that synthesized creatine
analogs and replaced the carboxylic acid with a large amide derivative12 (Fig 5) found no
activity in cells, presumably due to their inability to bind creatine kinase.3
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Conclusion
As empirically deduced from George Kenyon’s work11 and easily observed from
the crystal structure13, the size of functional group modifications in creatine is critically
important. Any modification to the carboxylic acid should be close to isosteric (similar
size), while substitution of the creatine methyl group is likely far more tolerant in size
(Scheme 1). Since carboxylic acids are highly deleterious to passive membrane
transport, we propose replacing the carboxylic acid with an isosteric, neutral,
unsubstituted amide. We also propose to substitute the methyl group with side chains
that are either more hydrophobic, fluorine-containing, or PEG-like, each a well-known
strategy for increasing passive transport across the BBB.
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CHAPTER FOUR
SYNTHESIS OF CREATINE DERIVATIVES
Introduction
Our proposed synthesis for the neutral amide derivative will be synthesized by
reacting chloroacetamide with commercially available primary amines to give the Nsubstituted-glycinamide. This N-substituted-glycinamide will then be guanidinylated
with 1H-pyrazole-1-carboxamidine HCl in the presence of DIEA base in DMF solution to
give the creatine derivative with the amide functional group (N-subtituted-N-amidinoglycinamide. The hydroxyl (OH) derivatives will exist as a salt form and will be
synthesized by reacting tert-butyl-bromoacetate with commercially available primary
amines to give the N-substituted-glycine-t-butyl-ester derivative. This can then be
guanidinylated with 1H-pyrazole-1-carboxamidine HCl in the presence of DIEA base and
DMF solution to give the creatine t-butyl-ester derivative. The ester group will then be
cleaved with trifluoroacetic acid in dichloromethane solutions. This method for the
guanidinylation will be a modified method demonstrated by Matsueda at al.1
Results and Discussion
Two types of amino acid derivatives were synthesized before amidination of the
amine to the guanidine was conducted. Table 1 shows the N-alkyl-t-butyl ester
derivatives. The yields were marginal to reasonable, with compound 7 having the lowest
yield of 24% and compound 5 having the highest yield of 74%. Since only 100 mg of the
final creatine derivative is needed for cell and zebrafish testing, no optimization of the
synthetic procedure was undertaken. Also, since an excess amount of amine was used for
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each reaction, compounds were purified by flash column chromatography over silica gel.
Surprisingly, use of bases such as Na2CO3 often resulted in decomposition of the
products, so the excess amine equivalents were used both to supress dialkylation and to
act as a base. 1H and 13C NMR spectra were collected for each compound to ensure
compound purity before being used for the guanidinylation step of the reaction.

Table 2 summarizes the N-alkyl-glycinamide derivatives. Since chloride is not as
good of a leaving group as bromide or iodide, substoichiometric potassium iodide was
added to the reaction to accelerate the alkylation reaction. The chloride on the
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chloroacetamide was replaced by the iodide in situ yielding a mixture of the relatively
inert chloroacetamide and the more reactive iodoacetamide. The iodoacetamide can
irreversibly undergo the SN2 reaction with the amine more readily to give the Nglycinamide derivative. Chloroacetamide was used instead of iodoacetamide because
chloroacetamide is less expensive compared to iodoacetamide. The yields were marginal
to high, with compound 11 having the lowest yield of 25% and compounds 8 and 13
having the highest yield of 93%. Again, no optimization of the synthetic procedure was
undertaken at this stage in the discovery process because only 100 mg of the final
creatine derivatives is necessary. Since an excess amount of amine was used for each of
the reactions, the compounds were purified by flash column chromatography over silica
gel to remove the excess amine as well as the chloride salt formed during reaction. 1H
and 13C NMR spectra were collected for each compound to ensure compound purity
being used for the guanidinylation step of the reaction (refer to SI for NMR).
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Once the different amino acid derivatives were synthesized, they were amidinated
using 1H-pyrazole-1-carboxamidine HCl as summarized in Table 3. Guanidinylation was
performed on the N-substituted-glycinamide derivatives but not the N-glycine-t-butyl
ester derivatives. This is due to N-substituted-glycine t-butyl ester derivatives being
more difficult to purify. The amidination reactions used DIEA and DMF solution to give
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the guanidinylated acetamide salt derivatives. For compounds 14 and 15, the amount of
DIEA used was 1.2 eq with respect to the N-substituted-glycinamide derivative. Since
the guanidine protons exchange rapidly in D2O, monitoring the reaction was not
straightforward using 1H NMR. However, since the creatine analog products contains a
highly electropositive carbon and a permanetly postive charge on the guanidine nitrogens,
we should expect to see a downfield shift in the protons closest to the positive charge due
to deshielding.

Mild downfield shifts were indeed observed in the 1H NMR for compound 14
(Figure 1.2) when compare to the 1H NMR of compound 7 (Figure 1.1).

13

C NMR

spectra, however, reveal only one peak in the carbonyl region, and therefore suggested
that the amidination reaction did not occur and that the modest downfield shifts in the 1H
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NMR were likely due to protonation of the amine. Examination of the reaction mixture
or product by MALDI did not yield any peaks, corresponding to either starting material
or product.

Fig1.1 1H NMR of N-ethyl glycinamide (7).
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Fig 1.2 1H NMR originally interpreted as N-ethyl-N-amidino-glycinamide (14).

Fig 2.1 13C NMR of the N-ethyl glycinamide (7).

40

Fig 2.2 13C NMR of reaction product of 7 with 1H-pyrazole-1-carboxamidine
(clearly not N-ethyl-N-amidino-glycinamide (14) due to the missing guanidine carbon
peak).
Since we likely merely obtained the protonated starting material, we decided to
increase the amount of base in the reaction. Hence, compound 16 was synthesized in the
same fashion as compounds 14 and 15 but with more DIEA base (5 eq instead of 1.2 eq).
As shown in the 1H NMR of the N-butyl glycinamide derivative (16) (Figure
3.1), the two protons on the α-carbon with respect to the carbonyl group have a chemical
shift of 3.180 ppm, once guanidinylated, the protons has a chemical shift of 3.953 ppm
(Figure 3.2). This far more substantial downfield shift is consistent with the formation of
N-butyl-N-amidino-glycinamide (16) but of course requires confirmation via 13C NMR.
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Fig3.1 1H NMR of N-butyl glycinamide derivative (9).

Fig 3.2 1H NMR of N-butyl-N-amidino-glycinamide (16).
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For compound 16 we did see an extra peak show up in the 13C NMR (Figure 4.1).
This indicates that a guanidine-containing product was synthesized. However, creatine
has the ability to cyclize to form creatinine. Therefore, we also collected 13C NMR
spectra of commercially available creatine monohydrate (Figure 4.2) and creatinine
(Figure 4.3) for comparison to our derivatives. The comparison clearly demonstrated
that a creatinine analog (Figure 5.1) was synthesized instead of a creatine analog (Figure
5.2) under these conditons (although for a creatinine product to form the amidination
reaction must have been successful). Elemental analysis also confirmed that compound
16 was indeed the creatinine analog.

Fig 4.1 13C NMR of the N-butyl-N-amidino-glycinamide (16).
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Fig 4.2 13C NMR of commercially available creatine monohydrate.

Fig 4.3 13C NMR of commercially available creatinine.
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Fig 5.1 Structure of N-butyl-N-amidino-gylcinamide creatinine. Fig 5.2 Structure of the
desired N-butyl-N-amidino-glycinamide (16).
Since the amidination reaction with 1H-pyrazole-1-carboxamidine HCl was lowyielding in producing product and unsuccessful, we decided to try a different method.
Instead of using 1H-pyrazole-1-carboxamidine, we decide to try the synthesis with diboc
thiourea. Diboc thiourea is commercially available, however, it is quite expensive
(~$100/g) therefore we had to synthesize the material before guanidinylation could take
place. Diboc thiourea was synthesized using a modified procedure from literature.2
Table 4 summerizes the N-N’-diboc-N-substituted-N-amidino-glycinamide
derivative before and after cleavage of the boc group. The N-glycinamide derivative
reacts with diboc thiourea, DIEA and DIC in a 5:1 DCE:DMF solution to give the N-N’diboc-N-substituted-N-amidino-glycinamide derivative. The boc groups were cleaved in
a 70:30 TFA:DCM solution overnight.
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Diboc-thiourea is a more effective amidination electrophile compared to pyrazole
carboxamidine because the electropositive carbamate carbonyl inductively withdraws
electron density from the thione carbon in the thiourea. Significantly higher yields can be
obtained from the reaction using activation with HgCl2 to form the unstable but highly
active diboc-carbodiimide in situ. This optimization was not initially investigated until it
was clear whether this route would yield creatine or creatinine derivative.
We were successful in synthesizing compounds 17 and 18 as noted by the 1H and
13

C NMR spectra. The 1H NMR indicated that the N-N’-diboc-amidino-glycinamide (17)

was synthesized due to the appearance of the singlet peak at 1.524ppm for compound 17
(Figure 6.2) and 1.516ppm for compound 18 (refer to SI for NMR). This singlet peak
corresponds to the 18 protons from the two boc groups on the guanidine. We also noted a
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downfield shift in the 1H NMR, when compared to the starting material for both
compound 17 (Figure 6.1) and 18 (Refer to SI for NMR). This downfield shift is caused
by the nitrogen and the boc groups on the guanidine.

Figure 6.1 1H NMR of N-isobutyl-glycinamide (8).
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Figure 6.2 1H NMR of N-isobutyl-N-diboc-amidino-glycinamide (17).
13

C NMR also confirms synthesis was successful by the appearance of the

guanidine carbon at 171.13 ppm for compound 17 (Figure 6.3) and at 171.29 ppm for
compound 18 (refer to SI for NMR). For compound 17, not only were we able to see the
guanidine peaks, but we were also able to see both the quaternary carbon peaks located
on the boc group of the guanidine (Figure 6.4). This further confirms that synthesis of
N-N’-diboc-amidino-glycinamide (17) derivatives was successful.
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Figure 6.3 13C NMR of N-isobutyl-N-diboc-amidino-glycinamide (17).

Figure 6.4 13C NMR of N-butyl-N-amidino-glycinamide (18). As shown in the
13

C NMR, a new peak appears at 171.15 ppm and 171.29 ppm for N-isobutyl-N-diboc-

amidino-glycinamide (17) and N-butyl-N-diboc-amidino-glycinamide (18) respectively.
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Not only did we see the guanidine carbon peak but for the compound 18 (Fig 6.4) we
were also able to see the carbon peaks coming from the boc group at 162.07 ppm and
152.61 ppm. This further indicates that the N-N’-diboc-amidino-glycinamide derivatives
were synthesized successfully for compounds 17 and 18.
Compound 19 was synthesized successfully as indicated by the 1H and 13C NMR
and elemental analysis. For compound 19, the boc group was cleave with a 70:30
TFA:DCM solution overnight (Refer to SI). The 1H NMR indicates a downfield shift due
to the permanent positive charge located on the guanidine (Figure 7.1). In the 13C NMR
of compound 19 (Figure 7.2), we were able to see the loss of the boc groups indicating
that the boc groups had successfully been removed. When the 13C NMR of compound 19
was compared to the 13C NMR of creatine monohydrate and creatinine, compound 19
resembled creatine (Figure 4.2) more than creatinine (Figure 4.3).

Figure 7.1 1H NMR of N-isobutyl-N-amidino-glycinamide (19).
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Figure 7.2 13C NMR of N-isobutyl-N-amidino-glycinamide (19).
Elemental analysis also confirm compound 19 was indeed the creatine analog and
not creatinine analog. The percentage of the atoms found from the elemental analysis
suggest that each positively charge guanidine for compound 19 is surround by two TFAcounterion (Figure 7.3). Therefore compound 19 was successfully synthesized utilizing
the diboc thiourea method.

Fig 7.3 Structure of compound 19 with 2 TFA counter
ions. The percentage from the elemental analysis were C, 32.73, H, 4.37, N, 13.74, O,
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21.19, F, 27.97 which is consistent with the theoretical elemental analysis of C, 33.01, H,
4.53, N, 14.00, O, 19.99, F, 28.48.
Compound 20 was also successfully synthesized. (Refer to SI for NMR).
Elemental analysis was not performed on compound 20 since the guanidine peak in 13C
NMR was the same as in compound 19, suggesting that compound 20 is indeed the
creatine analog and not the creatinine analog. This was also determined by comparing
the 13C NMR of compound 20 with the 13C NMR of compound 9 (Fig 4.1). The
creatinine derivative guanidine peak appears at 189 ppm in 13C NMR (Fig 4) while the
creatine derivative guanidine peak appears at around 172ppm.

Conclusion
Using 1H-pyrazole-1-carboxamidine HCl as the guanidinylating agent proved to
be unsuccessful. Using a smaller amount of DIEA base gave us our starting material
back and adding excess DIEA base causes the reaction to overreact to form the creatinine
derivatives. However, we were able to synthesize creatine derivatives with the Nsubstituted-glycinamide using diboc thiourea as the guanidinylating reactant. The yields
are low to marginal and could potentially be increased by allowing the reaction to stir for
a longer period of time. We were unable to synthesize creatine derivatives with the
hydroxyl end group. When the reaction was performed with the N-substituted-glycine-tbutyl ester derivative with diboc thiourea, the syntheses were very slow and there were
issues with the purification process; therefore, in the future we would like to try other
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methods until we establish one that works for the synthesis of creatine derivatives with
the hydroxyl end group.
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Supplementary Information

Materials and Methods
Materials: Creatine monohydrate and creatinine were purchased from TCI.
Triflouroethylamine, di-tert-butyl dicarbonate (boc anhydride) and
diisopropylcarbodiimide (DIC) were purchased from Oakwood Chemicals.
Diisopropylethylamine (DIEA) were purchased from Chem-Impex. Sodium hydride
(NaH), thiourea, chloroacetamide, and all other amines were purchased from Alfa Aesar.
Tert-butyl bromoacetate and 1H-pyrazole-1- carboxamidine hydrochloride were
purchased from AK Scientific. All chemicals were used without further purification.
General: Samples were purified by silica flash column chromatography in various ratios
of dichloromethane (DCM), methanol (MeOH) and 1% concentrated ammonium
hydroxide (NH4OH) solution or ethyl acetate (EA) and hexane solution. Once purified,
NMR were collected at 298 K on a Bruker Advance 300 and a Bruker Advance 500
NMR spectrometer. All 1H and 13C NMR chemical shifts are reported as δ values in parts
per million (ppm) relative to tetramethylsilane via residual solvent. Elemental analysis
was performed by Atlantic Microlabs, Inc. Melting points were determined using a
Stanford Research Systems Digimelt MPA 160 model.
General procedure for preparation of N-substitued glycine ester derivatives
A solution of the amine (125 mmol, 1 eq) in ~50 mL of acetonitrile (ACN) was cooled to
0°C in an ice bath. A solution of tert-butyl-bromoacetate (25 mmol, 1 eq) in ~50 mL of
ACN was added dropwise over ~30 minutes using an addition funnel. The ice bath was
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removed and, after warming to room temperature, the reaction was stirred for three to
five days. The solvent was then removed under vacuum and the residue dissolved in
dichloromethane and purified by silica flash column chromatography.
N-methylglycine tert-butyl ester (1)
The mobile phase for the chromatography was a mixture of dichloromethane, (DCM)
methanol (MeOH) and 1% concentrated ammonium hydroxide solution (NH4OH)
starting at 1% MeOH and increasing to 5%. The compound was recovered as a yellow
liquid with a Rf of 0.33 in 5% MeOH in DCM.
1

H NMR (500 MHz, D2O): δ 3.182 (s, 2H), 2.216 (s, 3H), 1.372 (s, 9H).
C NMR (125 MHz, D2O): δ 172.86, 83.19, 52.19, 34.12, 27.20.

13

N-ethylglycine tert-butyl ester (2)
The mobile phase for the chromatography was a mixture of 94% DCM, 5% MeOH and
1% concentrated NH4OH solution. The compound was recovered as a clear liquid. The
carbonyl signal in the 13C NMR was not observed due to limited solubility, but the
presence of the tert-butyl ester signal in 1H NMR clearly demonstrated the carbonyl must
be present.
1

H NMR (500 MHz, D2O): δ 3.672 (s, 2H), 2.951, 2.936 (d, 2H), 1.383 (s, 9H), 1.165-

1.136 (t, 3H).
C NMR (125 MHz, D2O): δ 47.98, 42.93, 29.72, 27.29, 10.52

13

N-isobutylglycine tert-butyl ester (3)
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The mobile phase for the chromatography was a mixture of DCM, MeOH and 1%
concentrated NH4OH solution starting at 0% MeOH and increasing to 5%. The
compound was a light brown powder with a Rf of 0.50 in 5% MeOH in DCM.
1

H NMR (500 MHz, D2O): δ 3.201 (s, 2H), 2.279-2.265 (d, 2H), 1.660-1.606 (s, 1H),

1.365 (s, 1H), 0.793-0.780 (d, 6H).
C NMR (125 MHz, D2O): δ 173.18, 83.45, 56.29, 50.91, 30.34, 27.36, 19.85.

13

N-butylglycine tert-butyl ester (4)
The mobile phase for the chromatography was a mixture of DCM, MeOH and 1%
concentrated NH4OH solution starting at 1% MeOH and increasing to 5%. The
compound was a light yellow liquid with a Rf of 0.53 in 3% MeOH in DCM.
1

H NMR (500 MHz, CDCl3): δ 3.299 (s, 2H), 2.608-2.579 (t, 2H), 1.501-1.1.455 (m, 2H),

1.466 (s, 9H), 1.385-1.340 (m, 2H) 0.938-0.908 (t, 3H).
C NMR (125 MHz, CDCl3): δ 171.67, 81.15, 51.70, 49.22, 32.09, 28.15, 20.44, 13.95

13

N-methoxypropylglycine tert-butyl ester (5)
The mobile phase for the chromatography was a mixture of DCM, MeOH and 1%
concentrated NH4OH solution starting at 2% MeOH and increasing to 3%. The
compound was a light yellow liquid with a Rf of 0.35 in 3% MeOH in DCM.
1

H NMR (500MHz, D2O): δ 3.434-3.408 (m, 2H), 3.242 (s, 3H), 3.202 (s, 2H), 2.521-

2.492 (t, 2H), 1.678-1.637 (m, 2H) 1.369 (s, 9H).
C NMR (75 MHz, D2O): δ 172.92, 83.13, 70.60, 57.73, 50.66, 45.29, 28.38, 27.25.

13

N-tertbutylglycine tert-butyl ester (6)
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The mobile phase for the chromatography was a mixture of DCM, MeOH and 1%
concentrated NH4OH solution starting at 2% MeOH and increasing to 3%. The
compound was isolated as a white solid.
1

H NMR (300MHz, CDCl3): δ 3.312 (s, 2H), 1.430 (s, 9H), 1.109 (s, 9H).
C NMR (75 MHz, CDCl3): δ 171.44, 81.46, 51.16, 45.16, 28.40, 28.02.

13

General procedure for preparation of N-substituted glycinamide derivatives
A solution of the amine (125 mmol, 5 eq) in ~100 mL of ACN was cooled to 0°C in an
ice bath. A solution of chloroacetamide (25 mmol, 1 eq) in ~100 mL of ACN was added
dropwise over ~30 minutes using an addition funnel. Potassium iodide (~2 g) was added,
then the ice bath was removed and, after warming to room temperature, the reaction
vessel was stirred for three to five days. The solvent was then removed under vacuum
and the residue dissolved in dichloromethane and purified by silica flash column
chromatography.
N-ethyl glycinamide (7)
The mobile phase for the chromatography was a mixture of DCM, MeOH and 1%
concentrated NH4OH solution starting at 3% MeOH and increasing to 20%. The
compound was isolated as an off- white solid with a Rf of 0.26 in 10% MeOH in DCM.
1

H NMR (500 MHz, D2O): δ 3.225 (s, 2H), 2.527-2.483 (q, 2H), 0.985-0.956 (t, 3H).
C NMR (125 MHz, D2O): δ 176.76, 50.03, 42.65, 13.36.

13

N-isobutyl glycinamide (8)
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The mobile phase for the chromatography was a mixture of DCM, MeOH and 1%
concentrated NH4OH solution starting at 3% MeOH and increasing to 15%. The
compound was a light brown powder with a Rf of 0.51 in 10% MeOH in DCM.
1

H NMR (500 MHz, CDCl3): δ 7.150 (s, 1H), 6.173 (s, 1H), 3.253 (s, 2H), 2.433-2.420

(d, 2H), 1.728-1.702 (m, 1H), 0.931-0.917 (d, 6H).
C NMR (125 MHz, CDCl3): δ 176.87, 56.26, 50.68, 27.40, 19.70.

13

N-butyl glycinamide (9)
The mobile phase for the chromatography was a mixture of DCM, MeOH and 1%
concentrated NH4OH solution starting at 5% MeOH and increasing to 7%. The
compound was an off-white solid with a Rf of 0.53 in 10% MeOH in DCM.
1

H NMR (300 MHz, D2O): δ 3.180 (s, 2H), 2.455-2.407 (t, 2H), 1.366-1.292 (m, 2H),

1.235-1.161 (m, 2H), 0.788-0.739 (t, 3H).
C NMR (75 MHz, D2O): δ 176.75, 50.44, 47.95, 30.67, 19.67, 13.10.

13

N-methoxypropyl glycinamide (10)
The mobile phase for the chromatography was a mixture of DCM, MeOH and 1%
concentrated NH4OH solution starting at 3% MeOH and increasing to 15%. The
compound was a thick yellow orange liquid with a Rf of 0.47 in 10% MeOH in DCM.
1

H NMR (500 MHz, D2O): δ 3.439-3.414 (m, 2H), 3.241 (s, 3H), 3.219 (s, 2H), 2.546-

2.517 (t, 2H), 1.696-1.630 (m, 2H).
C NMR (125 MHz, D2O): δ 176.37, 70.52, 57.71, 50.37, 45.40, 28.28

13

N-trifluoroethyl glycinamide (11)
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The mobile phase for the chromatography was a mixture of DCM, MeOH and 1%
concentrated NH4OH solution starting at 0% MeOH and increasing to 15%. The
compound was isolated as a white solid with a Rf of 0.33 in 10% MeOH in DCM. .
1

H NMR (500 MHz, D2O): δ 3.325 (S, 2H), 3.219-3.161 (q, 2H).
C NMR (125 MHz, D2O): δ 176.39, 128.72-122.10, 50.27, 49.10-48.85.

13

N-tert-butyl-2-chloroacetamide (12)
Tert-butylamine (2.5 g, 34.15 mmol, 1 eq) and diisopropylethylamine (23.8 mL, 136.7
mmol, 4 eq) were dissolved in DCM (100 mL) and stirred at 0°C on an ice bath. 2chloroacetyl chloride (6.53 mL, 82.03 mmol, 2.4 eq) was added drop wise using an
addition funnel. The sample was taken off the ice bath and allowed to warm to room
temperature for 16 hours. The crude reaction was concentrated under vacuum until dry
and resuspended in ethyl acetate and transferred to a separatory funnel. The organic layer
was washed with 2N HCl once and dried over Na2SO4. The solvent was removed under
vacuum. The sample was purified by column chromatography over silica gel in DCM and
MeOH starting at 0%MeOH and increasing to 20%. The compound was isolated as a
light brown solid with a Rf of 0.35 in DCM.
1

H NMR (500 MHz, CDCl3): δ 6.385 (s, Broad, 1H), 3.956 (s, 2H), 1.397 (s, 9H).
C NMR (125 MHz, CDCl3): δ 164.87, 51.74, 42.92, 28.49.

13

Methylamine N-t-butylacetamide (13)
A solution of methylamine (40% w/w in aq sol) (6.03 g, 77.652 mmol, 5 eq) in~50 mL of
ACN was cooled to 0°C in an ice bath. A solution of t-butyl-chloroacetamide (2.315 g,
15.530 mmol, 1 eq) in ~50 mL of ACN was added dropwise using an addition funnel.
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Potassium iodide (~2 g) was added, then the ice bath was removed and, after warming to
room temperature, the vessel was stirred for five days. The solvent was then removed
under vacuum and the residue dissolved in dichloromethane and purified by silica flash
column chromatography. The mobile phase for the chromatography was a mixture of
DCM, MeOH and 1% concentrated NH4OH solution starting at 5% MeOH and
increasing to 7%. The compound was a thick, dark orange-brown liquid with an Rf of
0.31 in 7% MeOH in DCM.
1

H NMR (500 MHz, CDCl3): δ 3.138 (s, 1H), 2.418 (s, 3H), 1.374 (s, 9H).
C NMR (125 MHz, CDCl3): δ 170.57, 55.26, 50.49, 36.55, 28.79.

13

General procedure for preparation of N-substituted-N-amidino-glycinamide
derivatives
To a solution of N-substituted-glycinamide (14 mmol, 1eq) in 20 mL dimethylformamide
(DMF) under nitrogen was added a solution of 1H-pyrazole-1-carboxamidine (16.8
mmol, 1.2 eq) and DIEA (16.8 mmol, 1.2 eq) in 5 mL of DMF in one portion. The
reaction mixture was stirred under nitrogen at room temperature for five days. The
solvent was then removed under vacuum and the remaining residue was dissolved in a
minimum amount of MeOH. The product was then precipitated out with ether, vacuum
filtered, rinsed with ether and then left to dry overnight.
N-ethyl-N-amidino-glycinamide (14)
The sample was a white powder. The guanidine signal in the 13C NMR was not
observed indicating the precipitate formed was not our product but instead was
protonated starting material.
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1

H NMR (500 MHz, D2O): δ 3.807 (s, 2H), 3.074-3.030 (q, 2H), 1.224-1.194 (t, 3H).
C NMR (125 MHz, D2O): δ 168.53, 47.12, 42.92, 10.36.

13

N-Methoxypropyl-N-amidino-glycinamide (15)
The sample was a white powder. The guanidine signal in the 13C NMR was not observed
indicating that the precipitate formed was not our product but instead was protonated
starting material.
1

H NMR (500 MHz, D2O): δ 3.810 (s, 1H), 3.508-3.469 (t, 2H), 3.256 (s, 3H), 3.117-

3.069 (t, 2H), 1.929-1.863 (m, 2H).
C NMR (125 MHz, D2O): δ 168.39, 69.83, 58.11, 47.71, 46.14, 25.32.

13

N-butyl-N-amidino-glycinamide (16)
To a solution of N-butyl-glycinamide (0.5 g, 3.8 mmol, 1eq) in 10 mL
dimethylformamide (DMF) under nitrogen was added a solution of 1H-pyrazole-1carboxamidine (0.68 g, 4.6 mmol, 1.2 eq) and DIEA (3.3 g, 19.2 mmol, 1.2 eq) in 1 mL
of DMF in one portion. The reaction mixture was stirred under nitrogen at room
temperature for five days. The solvent was then removed under vacuum and the
remaining residue was dissolved in a minimum amount of MeOH. The protonated
starting material was then precipitated out with ether and vacuum filtered. The remaining
solution was then removed under vacuum and the residue was resuspended in a minimum
of MeOH and dried on to a small amount of silica. Once the silica dried, sample was
purified by silica flash column chromatography. The mobile phase for the
chromatography was a mixture of DCM and MeOH starting at 2% MeOH and increasing
to 10%. The compound was a white powder with a Rf of 0.26 in 10% MeOH.
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1

H NMR (500 MHz, D2O): δ 3.953 (s, 2H), 3.301-3.272 (t, 2H), 1.526-1.467 (m, 2H),

1.260-1.185 (m, 2H), 0.821-0.792 (t, 3H).
C NMR (125 MHz, D2O): δ 189.15, 168.70, 54.20, 43.50, 28.99, 19.19, 12.87.

13

Elemental analysis of N-butyl-N-amidino-glycinamide (16)
Analysis Calculation: C, 40.29; H, 8.21; N, 26.85; Cl, 16.99. Found: C, 53.04; H, 7.85;
N, 26.44.
Elemental analysis suggests the product to be cyclic-butyl-N-amidino-glycinamide and
not linear butyl-N-amidino-glycinamide.
Procedure for preparation of di-Boc-thiourea
di-Boc-thiourea was synthesized using a modified procedure reported in the literature.1
A solution of thiourea (5.71 g, 75 mmol, 1 eq) in 100 mL of tetrahydrofuran (THF) under
nitrogen in a 2 liter side arm flask was cool to 0°C in an ice bath. NaH in mineral oil (7.5
g, 187.5 mmol, 2.5 eq) was added. After 10 minutes, the 0°C ice bath was removed and
the reaction mixture was stirred at room temperature for 20 minutes. The reaction
mixture was cooled back to 0°C and then boc anhydride was added neat (38 mL, 165
mmol, 2.2 eq). The reaction was stirred on ice for 1 hour and afterwards for 4 hours at
room temperature. The reaction was cooled back to 0°C with an ice bath and the solution
was quenched with 80 mL of NaHCO3. The reaction mixture was transferred into 500
mL of H2O and extracted with 250 mL of ethyl acetate three times. The organic layer
was dried over sodium sulfate, filtered, and the solvent was removed under vacuum. The
sample was divided into 3 portions and purified by silica flash column chromatography in
DCM. The sample was a white powder with an Rf of 0.54 in DCM.
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1

H NMR (500 MHz, CDCl3): δ 1.548 (S, 18)
C NMR (125 MHz, CDCl3): δ 177.73, 150.28, 84.15, 27.99

13

Melting Range: 128-130°C
Literature1 Value: 134-127°C
General procedure for preparation of N-substituted-N-di-Boc-amidino-glycinamide
derivatives
To a solution of N-substituted-glycinamide (7.7 mmol, 1eq) in 10 mL of 1:5 DMF:DCE
under nitrogen was added diboc thiourea (11.5 mmol, 1.5 eq), DIEA (11.5 mmol, 1.5 eq)
and DIC (11.5 mmol, 1.5 eq). The reaction mixture was stirred under nitrogen at room
temperature for seven days. The solvent was then removed under vacuum and the
residue was purified by silica flash column chromatography follow by a two solvent
system recrystallization.
N-isobutyl-N-diboc-amidino-glycinamide (17)
The mobile phase for the chromatography was a mixture of EA, and hexane starting at
80% EA and increasing to 100%. Recrystallization was performed in a 2 solvent system
of H2O and MeOH. The crystals were vacuum filter and rinsed with H2O and allowed to
dry overnight. The compound was a white solid with an Rf of 0.47 in 10% hexane in EA.
1

H NMR (500 MHz, CDCl3): δ 9.952 (s, 1H), 7.891 (s, 1H), 5.540 (s, 1H), 4.365 (s, 2H),

3.145-3.130 (d, 2H), 2.052-1.969 (m, 1H), 1.524 (s, 18H), 0.898-0.885 (d, 6H).
C NMR (125 MHz, CDCl3): δ 171.13, 156.69, 56.69, 50.92, 28.072, 27.23, 27.22,

13

19.84.
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Cleavage of the boc group from N-isobutyl-N-di-Boc-amidino-glycinamide to give Nisobutyl-N-amidino-glycinamide (19)
The sample was cleaved overnight using a 70:30 TFA:DCM mixture. The sample was a
white solid.
1

H NMR (500 MHz, D2O): δ 4.181 (s, 2H), 3.180-2.164 (d, 2H), 1.941-1.871 (m, 1H),

0.820-0.806 (d, 6H).
C NMR (125 MHz, D2O): δ 172.79, 156.89, 52.74, 51.74, 26.43, 18.68.

13

Elemental analysis of N-isobutyl-N-amidino-glycinamide (19)
Analysis Calculation: C, 35.04; H, 4.37; N, 13.74. Found: C, 33.01; H, 4.53; N, 14.00; F,
28.48
Elemental analysis suggests the product to be the linear N-isobutyl-N-diboc-amidinoglycinamide and not the cyclic N-isobutyl-N-diboc-amidino-glycinamide.
N-butyl-N-diboc-amidino-glycinamide (18)
The mobile phase for the chromatography was a mixture of EA, and hexane starting at
90% EA and increasing to 100% EA and 5% MeOH to 20% MeOH in DCM.
Recrystallization was performed in a 2 solvent system of H2O and MeOH. The crystals
were vacuum filtered and rinsed with H2O and allowed to dry overnight. The compound
was a light yellow powder with an Rf of 0.62 in 10% hexane in EA.
1

H NMR (500 MHz, CDCl3): δ 9.942 (s, 1H), 7.776 (s, 1H), 5.615 (s, 1H), 4.330 (s, 2H),

3.360-3.331 (t, 2H), 1.596-1.526 (m, 2H), 1.495 (S, 18H), 1.313-1.268 (m, 2H), 0.9350.905 (t, 3H).
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C NMR (125 MHz, CDCl3): δ 171.29, 162.07, 156.40, 152.61, 83.159, 80.16, 50.54,

13

29.78, 28.07, 19.80, 13.63.
Cleavage of boc group from N-butyl-N-di-Boc-amidino-glycinamide to give N-butyl-Namidino-glycinamide (20)
The sample was cleaved overnight using a 70:30 TFA:DCM solution mixture. The
sample was a white solid with a slight yellow tint.
1

H NMR (500 MHz, D2O): δ 4.182 (s, 2H), 3.388-3.358 (t, 2H), 1.540-1.510 (m, 2H),

1.257-1.211 (m, 2H), 0.817-0.788 (t, 3H).
C NMR (125 MHz, D2O): δ 172.89, 156.50, 52.14, 44.34, 28.20, 19.06, 12.77.

13
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